Unlocking the potential of established products: toward new incentives rewarding innovation in Europe.

about

Unlocking the potential of established products: toward new incentives rewarding innovation in Europe.

Item

http://www.wikidata.org/entity/Q41002125

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Unlocking the potential of est ...... ewarding innovation in Europe.

@en

type

Item

label

Unlocking the potential of est ...... ewarding innovation in Europe.

@en

prefLabel

Unlocking the potential of est ...... ewarding innovation in Europe.

@en

P1476

Unlocking the potential of est ...... ewarding innovation in Europe.

@en

P2093

Claudio Jommi

http://www.w3.org/2001/XMLSchema#string

Fernando Antoñanzas-Villar

http://www.w3.org/2001/XMLSchema#string

Gabrielle Nayroles

http://www.w3.org/2001/XMLSchema#string

Gérard de Pouvourville

http://www.w3.org/2001/XMLSchema#string

Jaime Espín

http://www.w3.org/2001/XMLSchema#string

Jürgen Wasem

http://www.w3.org/2001/XMLSchema#string

Keith Tolley

http://www.w3.org/2001/XMLSchema#string

Mondher Toumi

http://www.w3.org/2001/XMLSchema#string

Nello Martini

http://www.w3.org/2001/XMLSchema#string

Sandrine Frybourg

http://www.w3.org/2001/XMLSchema#string

P2860

Ethical and legal framework and regulation for off-label use: European perspective

Drug repositioning: identifying and developing new uses for existing drugs

Off-label prescribing: a call for heightened professional and government oversight

Diagnosing the decline in pharmaceutical R&D efficiency.

Off-label prescribing among office-based physicians.

Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview.

Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure.

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.

Economic impact of new active substance status on EU payers' budgets: example of dimethyl fumarate (Tecfidera(®)) for multiple sclerosis

Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications.

P304

1298190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/20016689.2017.1298190

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28740616

http://www.w3.org/2001/XMLSchema#string

P932

5508393

http://www.w3.org/2001/XMLSchema#string